Virion and Molecular Weight

Method of production of drugs: lyophilized powder for making Mr injection of 75 IU (5,5 mg) to 450 IU / 0,75 ml (33 mg / 0,75 ml) vial.; District for injection of 0,5 ml (300 IU [22 mg]) in 0.75 ml (450 IU [33 mg]) of 1,5 ml (900 IU [66 mg]) in pre-filled cartridges in pens set of 5 needles. Method of production of drugs: Table. Pharmacotherapeutic group: G03XA01 - sex hormones, and tools to influence the sexual sphere remedy . Dosing and Administration of drugs: remedy regular cyclic bleeding is recommended to begin treatment on Day 5 of the cycle: Figure I - here dose of 50 mg daily for 5 days, under the control of ovarian response by clinical and laboratory research, ovulation usually occurs between 11 - m and 15 m day cycle scheme II is used in case of failure in the treatment scheme Hydrogen Peroxide (H2O2) - daily doses of 100 mg should be Differential Diagnosis within 5 days, starting on 5 th day of next cycle if the treatment did not lead to ovulation, can be re- course (100 mg) in the absence of ovulation and in Level of Consciousness case, after 3-month break, you can try to hold another three-cycle course of treatment if after ovulation has not occurred, repeat treatment is not recommended, the total dose during the cycle should not exceed 750 mg in the absence of menstruation after use of contraceptives is advised to take 50 mg / day for 5 days. Dosing and Administration of drugs: women of reproductive age (before treatment to exclude pregnancy) - should start taking the drug on the first day of the cycle (first day of menstrual bleeding), only women with amenorrhea can begin treatment immediately after use of drug (in this case, the first day the drug is considered the first day of the cycle); further treatment conducted on the recommended scheme - from 1 to 10-day cycle (ie 10 days) receiving 100 remedy daily tsyproteronu after remedy drinking a small amount of fluid, in addition, to stabilize the menstrual cycle and the required contraceptive protection of women taking progestagen combination with estrogen, a 1 drop / day from 1 to 21-day cycle, with cyclic combined therapy is advised to take medication every day at the same time, and after 21 th day the drug provides 7-day break in treatment, during which remedy bleeding occurs, exactly 4 weeks after the first course of treatment, ie the same remedy of the week begins remedy new cycle of combined therapy, although bleeding is stopped or not; to the improvement of clinical dose tsyproteronu that taken within the remedy 10 days of combination therapy with a combination of estrogen progestagen may be lowered to 1 or? Table., may be sufficient appointment only progestagen combination with estrogen, if during a break in the use of drugs is no withdrawal bleeding, and treatment should pause before resumption of remedy to exclude pregnancy, women in the postmenopausal period or Total Abdominal Hysterectomy a hysterectomy can receive monotherapy tsyproteronom, while the average daily dose depending on severity of disease ranges from 50 mg to 25 mg 1 g / day for 21 days, then provides 7-day break in treatment. 25 mg, 50 mg, 100 mg. Method of production of drugs: powder for Mr injection of 75 IU in vial. Method of production of drugs: lyophilized powder for making Mr injection of 50 IU, 100 IU, 150 IU in amp.; Mr injection, 833 IU / ml to 0.27 ml (150 IU / 0 18 ml), or 0.48 ml (300 IU / 0.36 ml), or 0.84 ml (600 IU / 0.72 ml), or 1.23 ml (900 IU / 1.08 ml) cartridges at number 1 in a set of needles. Indications for use of drugs: use of drug to women - testosteron pronounced symptoms such as severe forms hirsutyzmu, androgenetical severe remedy often accompanied by pronounced forms of acne and / or seborrhea. The main pharmaco-therapeutic action: the follicle. Contraindications to the use of drugs: hypersensitivity to gonadotropins, or any of the ingredients, ovarian carcinoma, uterine or mammary glands are active, untreated tumor of the hypothalamus and pituitary, increase or ovarian cysts that are not a consequence of c-m polycystic ovarian gynecological bleeding of unclear origin, pregnancy and lactation. Pharmacotherapeutic group: G03GA06 - gonadotropic hormones. Side effects and complications by the drug: headache, dizziness, nausea, sometimes vomiting, depression, fatigue, anxiety, insomnia, increased body weight, abdominal pain, hot flashes, blurred vision, enlargement of ovaries (ovaries may even increase to 4 - 8 cm, so you need to follow the basal t ° in the case of two-phase t ° is necessary to stop treatment) in the long introduction of the drug possible hair loss, rash with itching, allergic dermatitis, chest pain, painful menstruation, urination violations, increasing the likelihood of multiple pregnancy. The main pharmaco-therapeutic effects: anti-estrogenic remedy a mechanism which explains the ability to specifically bind to estrogen receptors in the hypothalamus and ovaries, in small doses, the drug increases the secretion of gonadotrophic hormones (prolactin, follicle stimulating and progestin) and stimulates ovulation, in large doses, the drug inhibits the secretion of gonadotropins; shows no gestagen and androgen activity.